Selected research
Industry Research
Proto-Oncogene Drgu Industry Research Report 2026
Market perspective
The global Proto-Oncogene Drgu market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Proto-Oncogene Drgu is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Proto-Oncogene Drgu is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Proto-Oncogene Drgu is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Proto-Oncogene Drgu include ARIAD Pharmaceuticals, Bayer Healthcare, Bristol-Myers Squibb, ChemGenex Pharmaceuticals, Dexa Medica, Exelixis, Onyx Pharmaceuticals, Plexxikon and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Proto-Oncogene Drgu market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Proto-Oncogene Drgu Market by Company
ARIAD Pharmaceuticals
Bayer Healthcare
Bristol-Myers Squibb
ChemGenex Pharmaceuticals
Dexa Medica
Exelixis
Onyx Pharmaceuticals
Plexxikon
AstraZeneca
GlaxoSmithKline
Pfizer
Novartis
Eisai Pharmaceuticals
Proto-Oncogene Drgu Segment by Type
Imatinib (Gleevec)
Vemurafenib (Zelboraf)
Sorafenib (Nexavar)
Sunitinib (Sutent)
Pazopanib (Votrient)
Ponatinib (Iclusig)
Cabozantinib (Cabometyx and Cometriq)
Vandetanib (Caprelsa)
Dabrafenib (Tafinlar)
Axitinib (Inlyta)
Proto-Oncogene Drgu Segment by Application
Clinic
Hospital
Others
Proto-Oncogene Drgu Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Proto-Oncogene Drgu market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Proto-Oncogene Drgu and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Proto-Oncogene Drgu.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Proto-Oncogene Drgu manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Proto-Oncogene Drgu by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Proto-Oncogene Drgu in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Imatinib (Gleevec)
- Vemurafenib (Zelboraf)
- Sorafenib (Nexavar)
- Sunitinib (Sutent)
- Pazopanib (Votrient)
- Ponatinib (Iclusig)
- Cabozantinib (Cabometyx and Cometriq)
- Vandetanib (Caprelsa)
- Dabrafenib (Tafinlar)
- Axitinib (Inlyta)
Applications
- Clinic
- Hospital
- Others
Companies covered
- ARIAD Pharmaceuticals
- Bayer Healthcare
- Bristol-Myers Squibb
- ChemGenex Pharmaceuticals
- Dexa Medica
- Exelixis
- Onyx Pharmaceuticals
- Plexxikon
- AstraZeneca
- GlaxoSmithKline
- Pfizer
- Novartis
- Eisai Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Proto-Oncogene Drgu Market Size (2021-2032)
- 2.2.2 Global Proto-Oncogene Drgu Sales (2021-2032)
- 2.2.3 Global Proto-Oncogene Drgu Market Average Price (2021-2032)
- 2.3 Proto-Oncogene Drgu by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Imatinib (Gleevec)
- 2.3.3 Vemurafenib (Zelboraf)
- 2.3.4 Sorafenib (Nexavar)
- 2.3.5 Sunitinib (Sutent)
- 2.3.6 Pazopanib (Votrient)
- 2.3.7 Ponatinib (Iclusig)
- 2.3.8 Cabozantinib (Cabometyx and Cometriq)
- 2.3.9 Vandetanib (Caprelsa)
- 2.3.10 Dabrafenib (Tafinlar)
- 2.3.11 Axitinib (Inlyta)
- 2.4 Proto-Oncogene Drgu by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Proto-Oncogene Drgu Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Proto-Oncogene Drgu Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Proto-Oncogene Drgu Revenue of Manufacturers (2021-2026)
- 3.4 Global Proto-Oncogene Drgu Average Price by Manufacturers (2021-2026)
- 3.5 Global Proto-Oncogene Drgu Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Proto-Oncogene Drgu, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Proto-Oncogene Drgu, Product Type & Application
- 3.8 Global Manufacturers of Proto-Oncogene Drgu, Established Date
- 3.9 Global Proto-Oncogene Drgu Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 ARIAD Pharmaceuticals
- 4.1.1 ARIAD Pharmaceuticals Company Information
- 4.1.2 ARIAD Pharmaceuticals Business Overview
- 4.1.3 ARIAD Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 ARIAD Pharmaceuticals Proto-Oncogene Drgu Product Portfolio
- 4.1.5 ARIAD Pharmaceuticals Recent Developments
- 4.2 Bayer Healthcare
- 4.2.1 Bayer Healthcare Company Information
- 4.2.2 Bayer Healthcare Business Overview
- 4.2.3 Bayer Healthcare Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bayer Healthcare Proto-Oncogene Drgu Product Portfolio
- 4.2.5 Bayer Healthcare Recent Developments
- 4.3 Bristol-Myers Squibb
- 4.3.1 Bristol-Myers Squibb Company Information
- 4.3.2 Bristol-Myers Squibb Business Overview
- 4.3.3 Bristol-Myers Squibb Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bristol-Myers Squibb Proto-Oncogene Drgu Product Portfolio
- 4.3.5 Bristol-Myers Squibb Recent Developments
- 4.4 ChemGenex Pharmaceuticals
- 4.4.1 ChemGenex Pharmaceuticals Company Information
- 4.4.2 ChemGenex Pharmaceuticals Business Overview
- 4.4.3 ChemGenex Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 ChemGenex Pharmaceuticals Proto-Oncogene Drgu Product Portfolio
- 4.4.5 ChemGenex Pharmaceuticals Recent Developments
- 4.5 Dexa Medica
- 4.5.1 Dexa Medica Company Information
- 4.5.2 Dexa Medica Business Overview
- 4.5.3 Dexa Medica Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Dexa Medica Proto-Oncogene Drgu Product Portfolio
- 4.5.5 Dexa Medica Recent Developments
- 4.6 Exelixis
- 4.6.1 Exelixis Company Information
- 4.6.2 Exelixis Business Overview
- 4.6.3 Exelixis Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Exelixis Proto-Oncogene Drgu Product Portfolio
- 4.6.5 Exelixis Recent Developments
- 4.7 Onyx Pharmaceuticals
- 4.7.1 Onyx Pharmaceuticals Company Information
- 4.7.2 Onyx Pharmaceuticals Business Overview
- 4.7.3 Onyx Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Onyx Pharmaceuticals Proto-Oncogene Drgu Product Portfolio
- 4.7.5 Onyx Pharmaceuticals Recent Developments
- 4.8 Plexxikon
- 4.8.1 Plexxikon Company Information
- 4.8.2 Plexxikon Business Overview
- 4.8.3 Plexxikon Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Plexxikon Proto-Oncogene Drgu Product Portfolio
- 4.8.5 Plexxikon Recent Developments
- 4.9 AstraZeneca
- 4.9.1 AstraZeneca Company Information
- 4.9.2 AstraZeneca Business Overview
- 4.9.3 AstraZeneca Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 AstraZeneca Proto-Oncogene Drgu Product Portfolio
- 4.9.5 AstraZeneca Recent Developments
- 4.10 GlaxoSmithKline
- 4.10.1 GlaxoSmithKline Company Information
- 4.10.2 GlaxoSmithKline Business Overview
- 4.10.3 GlaxoSmithKline Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 GlaxoSmithKline Proto-Oncogene Drgu Product Portfolio
- 4.10.5 GlaxoSmithKline Recent Developments
- 4.11 Pfizer
- 4.11.1 Pfizer Company Information
- 4.11.2 Pfizer Business Overview
- 4.11.3 Pfizer Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Pfizer Proto-Oncogene Drgu Product Portfolio
- 4.11.5 Pfizer Recent Developments
- 4.12 Novartis
- 4.12.1 Novartis Company Information
- 4.12.2 Novartis Business Overview
- 4.12.3 Novartis Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Novartis Proto-Oncogene Drgu Product Portfolio
- 4.12.5 Novartis Recent Developments
- 4.13 Eisai Pharmaceuticals
- 4.13.1 Eisai Pharmaceuticals Company Information
- 4.13.2 Eisai Pharmaceuticals Business Overview
- 4.13.3 Eisai Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Eisai Pharmaceuticals Proto-Oncogene Drgu Product Portfolio
- 4.13.5 Eisai Pharmaceuticals Recent Developments
5 Global Proto-Oncogene Drgu Market Scenario by Region
- 5.1 Global Proto-Oncogene Drgu Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Proto-Oncogene Drgu Sales by Region: 2021-2032
- 5.2.1 Global Proto-Oncogene Drgu Sales by Region: 2021-2026
- 5.2.2 Global Proto-Oncogene Drgu Sales by Region: 2027-2032
- 5.3 Global Proto-Oncogene Drgu Revenue by Region: 2021-2032
- 5.3.1 Global Proto-Oncogene Drgu Revenue by Region: 2021-2026
- 5.3.2 Global Proto-Oncogene Drgu Revenue by Region: 2027-2032
- 5.4 North America Proto-Oncogene Drgu Market Facts & Figures by Country
- 5.4.1 North America Proto-Oncogene Drgu Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Proto-Oncogene Drgu Sales by Country (2021-2032)
- 5.4.3 North America Proto-Oncogene Drgu Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Proto-Oncogene Drgu Market Facts & Figures by Country
- 5.5.1 Europe Proto-Oncogene Drgu Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Proto-Oncogene Drgu Sales by Country (2021-2032)
- 5.5.3 Europe Proto-Oncogene Drgu Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Proto-Oncogene Drgu Market Facts & Figures by Country
- 5.6.1 Asia Pacific Proto-Oncogene Drgu Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Proto-Oncogene Drgu Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Proto-Oncogene Drgu Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Proto-Oncogene Drgu Market Facts & Figures by Country
- 5.7.1 South America Proto-Oncogene Drgu Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Proto-Oncogene Drgu Sales by Country (2021-2032)
- 5.7.3 South America Proto-Oncogene Drgu Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Proto-Oncogene Drgu Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Proto-Oncogene Drgu Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Proto-Oncogene Drgu Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Proto-Oncogene Drgu Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Proto-Oncogene Drgu Sales by Type (2021-2032)
- 6.1.1 Global Proto-Oncogene Drgu Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Proto-Oncogene Drgu Sales Market Share by Type (2021-2032)
- 6.2 Global Proto-Oncogene Drgu Revenue by Type (2021-2032)
- 6.2.1 Global Proto-Oncogene Drgu Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Proto-Oncogene Drgu Revenue Market Share by Type (2021-2032)
- 6.3 Global Proto-Oncogene Drgu Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Proto-Oncogene Drgu Sales by Application (2021-2032)
- 7.1.1 Global Proto-Oncogene Drgu Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Proto-Oncogene Drgu Sales Market Share by Application (2021-2032)
- 7.2 Global Proto-Oncogene Drgu Revenue by Application (2021-2032)
- 7.2.1 Global Proto-Oncogene Drgu Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Proto-Oncogene Drgu Revenue Market Share by Application (2021-2032)
- 7.3 Global Proto-Oncogene Drgu Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Proto-Oncogene Drgu Value Chain Analysis
- 8.1.1 Proto-Oncogene Drgu Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Proto-Oncogene Drgu Production Mode & Process
- 8.2 Proto-Oncogene Drgu Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Proto-Oncogene Drgu Distributors
- 8.2.3 Proto-Oncogene Drgu Customers
9 Global Proto-Oncogene Drgu Analyzing Market Dynamics
- 9.1 Proto-Oncogene Drgu Industry Trends
- 9.2 Proto-Oncogene Drgu Industry Drivers
- 9.3 Proto-Oncogene Drgu Industry Opportunities and Challenges
- 9.4 Proto-Oncogene Drgu Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst